Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Panel To Help Define Target Population For Xifaxan Reuse In IBS-D

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA’s Gastrointestinal Drugs Advisory Committee Nov. 16 will review a trial design for evaluating the safety and efficacy of retreatment for the chronic condition with Silax’s antibiotic Xifaxan.

You may also be interested in...

Irritable Bowel Drugs From Salix, Actavis Await FDA Action In 2015

With new retreatment data in hand, Salix is again pursuing a supplemental claim for the antibacterial Xifaxan, while Actavis is seeking approval of eluxadoline, a new molecular entity with dual opioid receptor activity.

Committee Seeks More Information On Long-Term Use Of Xifaxan For IBS-D

Success in a single course of treatment is not enough to identify patients for long-term intermittent treatment with the antibiotic, the Gastrointestinal Drugs Advisory Committee tells FDA Nov. 16

GI Drugs Cmte. To Weigh Retreatment Study Design For Salix's Xifaxan In Irritable Bowel

On Nov. 16, FDA's outside advisors will discuss the design of clinical trials to evaluate the safety, efficacy and durability of response with repeat treatment cycles of rifaximin for diarrhea-predominant IBS.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts